Sulfhemoglobinemia is a rare, irreversible dyshemoglobinemia caused by incorporation of a sulfur atom into the porphyrin ring of hemoglobin, rendering it incapable of oxygen transport. [1-2] It classically presents as cyanosis disproportionate to the degree of clinical illness, with a normal or elevated PaO₂ on ABG, and does not respond to methylene blue — the key features distinguishing it from methemoglobinemia. [2-3]
1. History
- Ask about recent or chronic medication use: phenazopyridine (most common culprit), dapsone, sulfonamides, metoclopramide, phenacetin, and other sulfur-containing or oxidizing drugs [3-6]
- Duration and progression of cyanosis — often gradual onset over days to weeks [4]
- Timing relative to drug initiation (phenazopyridine cases often present after weeks of use) [4]
- Associated symptoms: fatigue, dyspnea, near-syncope, exercise intolerance [3]
- History of chronic constipation (endogenous hydrogen sulfide source) [4]
- Occupational or environmental exposure to hydrogen sulfide (industrial settings, sewage)
- Important negatives: no cardiac or pulmonary disease to explain cyanosis
2. Alarm Features
- Severe cyanosis with SpO₂ <85% unresponsive to supplemental oxygen [3]
- Syncope, altered mental status, or hemodynamic instability
- Concurrent hemolytic anemia (can occur with sulfhemoglobinemia-inducing agents) [7]
- Signs of end-organ hypoxia: chest pain, lactic acidosis, seizures
- Neonatal presentation — higher mortality risk [7]
3. Medications
- Causative agents: [2-6]
- Phenazopyridine (most commonly reported)
- Dapsone
- Sulfonamides (sulfamethoxazole)
- Metoclopramide (especially high-dose)
- Phenacetin, acetanilid
- Flutamide
- Methylene blue does NOT reverse sulfhemoglobinemia — this is a critical distinguishing point from methemoglobinemia [2-3]
- N-acetylcysteine in combination with metoclopramide has been implicated [5]
- Discontinuation of the offending agent is the primary intervention
4. Diet
- Chronic constipation is a recognized predisposing factor, as gut bacteria produce hydrogen sulfide (H₂S), which serves as the sulfur donor [4]
- Adequate fiber and hydration to prevent constipation may reduce endogenous H₂S production
- No specific acute dietary management; focus is on drug cessation
5. Review of Systems
- Respiratory: dyspnea, exercise intolerance (often milder than expected for degree of cyanosis)
- Cardiovascular: palpitations, chest pain, syncope/presyncope
- Neurologic: headache, dizziness, fatigue, altered mentation
- GI: constipation history, abdominal distension (H₂S-producing conditions)
- GU: dysuria or UTI symptoms (phenazopyridine use, or UTI as direct cause) [4][8]
- Skin: bluish-gray or greenish discoloration
6. Collateral History and Family History
- Confirm all medications including OTC drugs (phenazopyridine is available OTC) [4]
- Ask caregivers about duration and progression of skin color changes
- No hereditary form of sulfhemoglobinemia exists (unlike methemoglobinemia) — family history is primarily useful to exclude congenital methemoglobinemia [2][6]
- Social history: occupational H₂S exposure (petroleum, mining, sewage workers)
7. Risk Factors
- Chronic use of oxidizing drugs combined with a sulfur source [2]
- Chronic constipation (endogenous H₂S) [4]
- Recurrent UTIs or GI infections with H₂S-producing organisms (E. coli, Morganella morganii) [7-8]
- Prematurity/neonatal period (altered gut microbiome) [7]
- Occupational hydrogen sulfide exposure
8. Differential Diagnosis
- Methemoglobinemia — most important mimic; responds to methylene blue, co-oximetry directly measures MetHb [2-3]
- Carboxyhemoglobinemia — cherry-red skin, CO exposure history, elevated COHb on co-oximetry
- Cyanotic congenital heart disease — abnormal echocardiogram, history since birth
- Severe pneumonia/PE/ARDS — abnormal PaO₂ (unlike sulfhemoglobinemia)
- Low oxygen-affinity hemoglobin variants (e.g., Hb Kansas) — lifelong low SpO₂, hemoglobin electrophoresis diagnostic [9]
- Peripheral cyanosis from poor perfusion (shock, Raynaud's) — warm central cyanosis absent
Key distinguishing feature: In sulfhemoglobinemia, the patient appears more cyanotic than clinically ill, with a normal/high PaO₂ and failure to respond to methylene blue. [2-3]
9. Past Medical History
- Prior episodes of unexplained cyanosis
- Chronic constipation or GI dysmotility
- Recurrent UTIs or neurogenic bladder [8]
- G6PD deficiency (increases susceptibility to oxidant drug toxicity) [10]
- Spina bifida or other conditions predisposing to chronic infections [8]
10. Physical Exam
- Vital signs: SpO₂ characteristically low (70–85%) and does not improve with supplemental O₂; heart rate and blood pressure often normal in mild cases [3]
- Skin: Diffuse bluish-gray or greenish cyanosis — may appear more pronounced than methemoglobinemia at equivalent levels [11]
- Respiratory: Often clear lungs with no respiratory distress despite profound cyanosis
- Cardiovascular: Tachycardia if severe; otherwise unremarkable
- Neurologic: Usually normal unless severe; assess for altered mentation
- Blood appearance: Characteristically dark greenish-brown and does not turn red with oxygen exposure
11. Lab Studies
- ABG with co-oximetry: PaO₂ normal or elevated; standard co-oximeters may falsely report elevated MetHb (pseudomethemoglobinemia) because SulfHb absorbs at a similar wavelength (~620 nm) [2][12]
- Spectrophotometry (Evelyn-Malloy method): Gold standard — addition of cyanide eliminates MetHb absorption peak but does not affect SulfHb peak, confirming the diagnosis [2]
- CBC: May show anemia if concurrent hemolysis
- Reticulocyte count, LDH, haptoglobin, bilirubin: To evaluate for hemolytic anemia
- G6PD level: If oxidant drug exposure suspected [10]
- Lactate: To assess tissue oxygenation
- Newer co-oximeters with expanded wavelength analysis can directly quantify SulfHb [2][13]
12. Imaging
- Chest X-ray: To rule out pulmonary causes of cyanosis; expected to be normal in isolated sulfhemoglobinemia
- Echocardiography: If cardiac shunt is in the differential
- No specific imaging findings for sulfhemoglobinemia; imaging is used to exclude alternative diagnoses
13. Special Tests
- Spectrophotometric analysis with cyanide addition: Differentiates SulfHb from MetHb — cyanide converts MetHb to cyanmethemoglobin (eliminating the 620 nm peak) but does not affect SulfHb [2]
- HPLC (high-performance liquid chromatography): Can identify and quantify SulfHb [14]
- Raman spectroscopy: Emerging technique for differentiating SulfHb subtypes [1]
- Methylene blue challenge: Failure to improve cyanosis after methylene blue administration is a practical bedside clue [2-4]
14. ECG
- ECG is indicated to rule out cardiac causes of cyanosis and assess for ischemia in the setting of impaired oxygen delivery
- No specific ECG pattern for sulfhemoglobinemia
- Monitor for tachycardia, ST changes, or arrhythmias in severe cases with tissue hypoxia
15. Assessment
Sulfhemoglobinemia produces a "functional anemia" by rendering affected hemoglobin unable to carry oxygen. However, it is generally better tolerated than methemoglobinemia at equivalent levels because sulfhemoglobin causes a rightward shift of the oxygen-hemoglobin dissociation curve in unaffected hemoglobin, facilitating oxygen unloading to tissues. [2][12] Cyanosis becomes clinically apparent at SulfHb levels as low as 0.5 g/dL (compared to 1.5 g/dL for MetHb and 5 g/dL for deoxyhemoglobin). [2]
The condition is irreversible — sulfhemoglobin persists for the lifespan of the affected red blood cells (~120 days). [2] Severity depends on the percentage of hemoglobin affected and the patient's baseline cardiopulmonary reserve.
16. Treatment Plan
- Immediate: Discontinue the offending agent — this is the single most important intervention [3-4]
- Supportive oxygen: Supplemental O₂ will not significantly improve SpO₂ readings but may marginally improve dissolved oxygen delivery
- Methylene blue is NOT effective and should not be administered (or if given empirically for suspected MetHb, failure to respond should prompt consideration of SulfHb) [2-3]
- Transfusion: Simple RBC transfusion for symptomatic anemia or hemodynamic compromise [7-8]
- Exchange transfusion: Considered in severe, life-threatening cases to rapidly reduce the proportion of sulfhemoglobin [3][7]
- Treat underlying infection: If bacterial H₂S production is the cause (e.g., UTI, intestinal pathogen), appropriate antibiotics [7-8]
- Constipation management: Address chronic constipation to reduce endogenous H₂S [4]
- No pharmacologic antidote exists; resolution occurs only as affected RBCs are naturally cleared over ~120 days [2]
17. Disposition
- Admit if:
- Symptomatic (syncope, dyspnea at rest, altered mentation, hemodynamic instability)
- SulfHb levels high enough to cause significant functional anemia
- Concurrent hemolytic anemia
- Need for transfusion or exchange transfusion
- Neonatal or pediatric cases [7]
- Discharge if:
- Mild cyanosis without symptoms
- Offending agent identified and discontinued
- Stable hemoglobin and no hemolysis
- Reliable follow-up ensured
- Hematology consultation for confirmation of diagnosis, severe cases, or consideration of exchange transfusion
- Toxicology consultation if drug or toxin exposure is unclear
18. Follow Up / Return Precautions
- Follow-up within 1–2 weeks with repeat CBC and clinical assessment
- Cyanosis will gradually resolve over weeks to months as affected RBCs are cleared (~120-day RBC lifespan) [2]
- Return immediately for worsening dyspnea, syncope, chest pain, or new confusion
- Counsel to permanently avoid the causative agent
- Document the diagnosis prominently in the medical record and allergy list to prevent re-exposure
- If constipation was a contributing factor, establish a bowel regimen and follow up on adherence
References
1. Sulfhemoglobin Under the Spotlight - Detection and Characterization of SHb and HbFe-SH. — Stepanenko T, Zając G, Czajkowski A, et al. Biochimica Et Biophysica Acta. Molecular Cell Research. 2023.
2. Sulfhemoglobin Under the Spotlight - Detection and Characterization of SHb and HbFe-SH. — Stepanenko T, Zając G, Czajkowski A, et al. Biochimica Et Biophysica Acta. Molecular Cell Research. 2023.
3. Sulfhemoglobin Under the Spotlight - Detection and Characterization of SHb and HbFe-SH. — Stepanenko T, Zając G, Czajkowski A, et al. Biochimica Et Biophysica Acta. Molecular Cell Research. 2023.
4. Pseudomethemoglobinemia: A Case Report and Review of Sulfhemoglobinemia. — Lu HC, Shih RD, Marcus S, Ruck B, Jennis T. Archives of Pediatrics & Adolescent Medicine. 1998.
5. Pseudomethemoglobinemia: A Case Report and Review of Sulfhemoglobinemia. — Lu HC, Shih RD, Marcus S, Ruck B, Jennis T. Archives of Pediatrics & Adolescent Medicine. 1998.
6. Case Report: Phenazopyridine-Induced Sulfhemoglobinemia in an 83-Year-Old Presenting With Dyspnea. — Morales A, Walsh R, Brown W, Checinski P, Williams SR. The Journal of Emergency Medicine. 2021.
7. Case Report: Phenazopyridine-Induced Sulfhemoglobinemia in an 83-Year-Old Presenting With Dyspnea. — Morales A, Walsh R, Brown W, Checinski P, Williams SR. The Journal of Emergency Medicine. 2021.
8. Phenazopyridine-Induced Sulfhemoglobinemia. — Gopalachar AS, Bowie VL, Bharadwaj P. The Annals of Pharmacotherapy. 2005.
9. Phenazopyridine-Induced Sulfhemoglobinemia. — Gopalachar AS, Bowie VL, Bharadwaj P. The Annals of Pharmacotherapy. 2005.
10. An Adolescent Case of Sulfhemoglobinemia Associated With High-Dose Metoclopramide and N-Acetylcysteine. — Langford JS, Sheikh S. Annals of Emergency Medicine. 1999.
11. An Adolescent Case of Sulfhemoglobinemia Associated With High-Dose Metoclopramide and N-Acetylcysteine. — Langford JS, Sheikh S. Annals of Emergency Medicine. 1999.
12. Recommendations for diagnosis and treatment of methemoglobinemia. — Iolascon A, Bianchi P, Andolfo I, et al. American Journal of Hematology. 2021.
13. Recommendations for diagnosis and treatment of methemoglobinemia. — Iolascon A, Bianchi P, Andolfo I, et al. American Journal of Hematology. 2021.
14. Neonatal Sulfhemoglobinemia and Hemolytic Anemia Associated With Intestinal Morganella Morganii. — Murphy K, Ryan C, Dempsey EM, et al. Pediatrics. 2015.
15. Neonatal Sulfhemoglobinemia and Hemolytic Anemia Associated With Intestinal Morganella Morganii. — Murphy K, Ryan C, Dempsey EM, et al. Pediatrics. 2015.
16. A Case of Sulfhemoglobinemia Secondary to a Urinary Tract Infection. — Campagna G, Espaillat A, Pfeiffer T, et al. Journal of Pediatric Hematology/Oncology. 2020.
17. A Case of Sulfhemoglobinemia Secondary to a Urinary Tract Infection. — Campagna G, Espaillat A, Pfeiffer T, et al. Journal of Pediatric Hematology/Oncology. 2020.
18. How we diagnose and manage altered oxygen affinity hemoglobin variants. — Yudin J, Verhovsek M. American Journal of Hematology. 2019.
19. How we diagnose and manage altered oxygen affinity hemoglobin variants. — Yudin J, Verhovsek M. American Journal of Hematology. 2019.
20. FDA Drug Label. — Updated date: 2026-02-27. Food and Drug Administration.
21. FDA Drug Label. — Updated date: 2026-02-27. Food and Drug Administration.
22. On the Dysfunctional Hemoglobins and Cyanosis Connection: Practical Implications for the Clinical Detection and Differentiation of Methemoglobinemia and Sulfhemoglobinemia. — Askew SW, Baranoski GVG. Biomedical Optics Express. 2018.
23. On the Dysfunctional Hemoglobins and Cyanosis Connection: Practical Implications for the Clinical Detection and Differentiation of Methemoglobinemia and Sulfhemoglobinemia. — Askew SW, Baranoski GVG. Biomedical Optics Express. 2018.
24. Understanding pulse oximetry in hematology patients: Hemoglobinopathies, racial differences, and beyond. — Patterson S, Sandercock N, Verhovsek M. American Journal of Hematology. 2022.
25. Understanding pulse oximetry in hematology patients: Hemoglobinopathies, racial differences, and beyond. — Patterson S, Sandercock N, Verhovsek M. American Journal of Hematology. 2022.
26. A Case of Sulfhemoglobinemia and Emergency Measurement of Sulfhemoglobin With an OSM3 CO-oximeter. — Wu C, Kenny MA. Clinical Chemistry. 1997.
27. A Case of Sulfhemoglobinemia and Emergency Measurement of Sulfhemoglobin With an OSM3 CO-oximeter. — Wu C, Kenny MA. Clinical Chemistry. 1997.
28. Identification of Sulfhemoglobinemia After Surgical Polypectomy. — Harangi M, Mátyus J, Nagy E, et al. Clinical Toxicology. 2007.
29. Identification of Sulfhemoglobinemia After Surgical Polypectomy. — Harangi M, Mátyus J, Nagy E, et al. Clinical Toxicology. 2007.